DOI QR코드

DOI QR Code

Overexpression of RUNX3 Inhibits Malignant Behaviour of Eca109 Cells in Vitro and Vivo

  • Chen, Hua-Xia (Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University) ;
  • Wang, Shuai (Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University) ;
  • Wang, Zhou (Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University) ;
  • Zhang, Zhi-Ping (Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University) ;
  • Shi, Shan-Shan (Department of Obstetrics and Gynecology, Western Provincial Hospital Affiliated to Shandong University)
  • Published : 2014.02.28

Abstract

Runt-related transcription factor 3 (RUNX3) is a tumor suppressor gene whose reduced expression may play an important role in the development and progression of esophageal squamous cell cancer (ESCC). The aim of this study was to investigate the clinical relevance of RUNX3 in ESCC patients and effects of overexpression on biological behaviour of Eca109 cells in vitro and in vivo. Immunohistochemistry was performed to detect the clinical relevance of RUNX3 and lymph node metastasis in 80 ESCC tissues and 40 non-cancerous tissues using the SP method. RT-PCR and Western blotting were applied to assess the RUNX3 level and verify the Eca109 cell line with stable overexpression. Localization of RUNX3 proteins was performed by cell immunofluorescence. CCK-8 and Scrape motility assays were used to determine proliferation and migration and the TUNEL assay to analyze cell apoptosis. Invasive potential was assessed in cell transwell invasion experiments. In nude mice, tumorigenesis in vivo was determined. Results showed decreased expression of RUNX3 in esophageal tissue to be significantly related to lymph node metastasis (LNM) (P<0.01). In addition, construction of a recombinant lentiviral vector and transfection into the human ESCC cell line Eca109 demonstrated that overexpression could inhibit cell proliferation, migration and invasion, and induce apoptosis. The in vivo experiments in mice showed tumorigenicity and invasiveness to be significantly reduced. Taken together, our studies indicate that underexpression of RUNX3 in human ESCC tissue is significantly correlated with progression. Restoration of RUNX3 expression significantly inhibits ESCC cells proliferation, migration, invasion and tumorigenesis.

Keywords

Esophageal squamous cancer;RUNX3;lentivirus;overexpression;proliferation;apoptosis

References

  1. Soong R, Shah N, Peh B.K, et al (2009). The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer, 100, 676-9. https://doi.org/10.1038/sj.bjc.6604899
  2. Torquati A, O'rear L, Longobardi L, et al (2004). RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery, 136, 310-6. https://doi.org/10.1016/j.surg.2004.05.005
  3. Wang S, Liu H, Akhtar J, Chen HX, Wang Z (2013). Alteration of runt-related transcription factor 3 gene expression and biologic behavior of esophageal carcinoma TE-1 cells after 5-azacytidine intervention. Asian Pac J Cancer Prev, 14, 5427-33. https://doi.org/10.7314/APJCP.2013.14.9.5427
  4. Won YW, Lee M, Kim HA, Bull DA, Kim SW (2003). Hypoxiainducible plasmid expressing both miSHP-1 and HO-1 for the treatment of ischemic disease. J Control Release, 11, 22-8.
  5. Nevadunsky NS, Barbieri JS, Kwong J, et al (2009). RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecol Oncol, 112, 325-30. https://doi.org/10.1016/j.ygyno.2008.09.006
  6. Sakakura C, Miyagawa K, Fukuda KI, et al (2007). Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis. Oncogene, 26, 5927-38. https://doi.org/10.1038/sj.onc.1210403
  7. Subramaniam MM, Chan JY, Soong R, et al (2009). RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat, 113, 113-21. https://doi.org/10.1007/s10549-008-9917-4
  8. Subramaniam MM, Chan JY, Soong R, et al (2009). RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. Am J Gastroenterol, 104, 426-36. https://doi.org/10.1038/ajg.2008.141
  9. Sugiura H, Ishiguro H, Kuwabara Y, et al (2008). Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep, 19, 713-19.
  10. Sun ZG, Wang Z, Liu XY, Liu FY (2011). Mucin 1 and vascular endothelial growth factor C expression correlates with lymph node metastatic recurrence in patients with N0 esophageal cancer after Ivor-Lewis esophagectomy. World J Surg, 35, 70-7. https://doi.org/10.1007/s00268-010-0829-1
  11. Smith E, De Young NJ, Pavey SJ, et al (2008). Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer, 7, 75. https://doi.org/10.1186/1476-4598-7-75
  12. Tonomoto Y, Tachibana M, Dhar D.K, et al (2007). Differential expression of RUNX genes in human esophageal squamous cell carcinoma: downregulation of RUNX3 worsens patient prognosis. Oncology, 73, 346-56. https://doi.org/10.1159/000135350
  13. Ito K, Lim AC, Salto-Tellez M, et al (2008). RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell, 14, 226-37. https://doi.org/10.1016/j.ccr.2008.08.004
  14. Chen G, Wang Z, Liu XY, Liu FY (2009). Adjuvant radiotherapy after modified Ivor-Lewis esophagectomy: can it prevent lymph node recurrence of the mid-thoracic esophageal carcinoma? Ann Thorac Surg, 87, 1697-702. https://doi.org/10.1016/j.athoracsur.2009.03.060
  15. Dresner SM, Griffin SM (2000). Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg, 87, 1426-33. https://doi.org/10.1046/j.1365-2168.2000.01541.x
  16. Hiramatsu T, Osaki M, Ito Y, et al (2005). Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiology, 72, 316-24. https://doi.org/10.1159/000091329
  17. Ito K, Liu Q, Salto-Tellez M, et al (2005). RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res, 65, 7743-50. https://doi.org/10.1158/0008-5472.CAN-05-0743
  18. Kim HR, Oh BC, Choi JK, Bae SC (2008). Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J Cell Biochem, 105, 1048-58. https://doi.org/10.1002/jcb.21906
  19. Lau QC, Raja E, Salto-Tellez M, et al (2006). RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res, 66, 6512-20. https://doi.org/10.1158/0008-5472.CAN-06-0369
  20. Li QL, Ito K, Sakakura C, et al (2002). Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell, 109, 113-24. https://doi.org/10.1016/S0092-8674(02)00690-6
  21. Miyazono K, Suzuki H, Imamura T. (2003). Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci, 94, 230-34. https://doi.org/10.1111/j.1349-7006.2003.tb01425.x
  22. Nakagawa S, Kanda T, Kosugi S, et al (2004). Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg, 198, 205-11. https://doi.org/10.1016/j.jamcollsurg.2003.10.005
  23. Bangsow C, Rubins N, Glusman G, et al (2001). The RUNX3 gene sequence, structure and regulated expression. Gene, 279, 221-32. https://doi.org/10.1016/S0378-1119(01)00760-0

Cited by

  1. Inactivation of RUNX3 predicts poor prognosis in esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy vol.31, pp.12, 2014, https://doi.org/10.1007/s12032-014-0309-9
  2. Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells vol.34, pp.1, 2015, https://doi.org/10.1186/s13046-015-0160-7
  3. Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis vol.13, pp.6, 2016, https://doi.org/10.3892/mmr.2016.5108
  4. RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway vol.7, pp.5, 2016, https://doi.org/10.1111/1759-7714.12370